Fate Therapeutics Newsroom

Barclays Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsDec 11 04:31 ET

BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $3

Moomoo NewsDec 10 05:35 ET

Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development

TipRanksDec 10 04:50 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)

TipRanksDec 6 07:33 ET

TD Cowen Maintains Fate Therapeutics(FATE.US) With Hold Rating

Moomoo NewsDec 6 07:33 ET

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsDec 5 12:31 ET

BofA Securities Upgrades Fate Therapeutics to Neutral From Underperform, $3 Price Target

MT NewswiresNov 19 09:54 ET

A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $10

Moomoo NewsNov 19 08:01 ET

Fate Therapeutics Analyst Ratings

BenzingaNov 19 04:39 ET

Barclays Releases a Buy Rating on Fate Therapeutics (FATE)

TipRanksNov 19 03:55 ET

A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $6

Moomoo NewsNov 14 08:05 ET

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)

TipRanksNov 14 02:44 ET

A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10

Moomoo NewsNov 13 08:05 ET

Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)

TipRanksNov 13 05:42 ET

Fate Therapeutics Analyst Ratings

BenzingaNov 13 05:14 ET

Fate Therapeutics (FATE) Receives a Buy From Barclays

TipRanksNov 13 05:14 ET

TD Cowen Sticks to Its Hold Rating for Fate Therapeutics (FATE)

TipRanksNov 12 21:53 ET

Fate Therapeutics Analyst Ratings

BenzingaAug 22 07:36 ET

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5

Moomoo NewsAug 22 06:31 ET

Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones

TipRanksAug 22 06:29 ET